生物活性

• 描述Colfosceril palmitate (dipalmitoylphosphatidylcholine) is the primary surface-active agent of natural lung surfactant and the major constituent of exogenous surface replacement preparations^[3]. The use of beractant and colfosceril palmitate in premature infants has clearly decreased morbidity and mortality associated with RDS(respiratory distress syndrome)^[4]. Phosphatidylcholine and colfosceril palmitate in serum as well as xanthurenic acid, naphthalenesulfonic acid, and pimelylcarnitine in urine might be metabolic biomarkers due to their promising diagnostic potential at the early stage of the infection^[5]. Rescue therapy with colfosceril palmitate in infants with NRDS (neonatal respiratory distress syndrome) and birthweights over 1250g can result in substantial reductions in hospital resource utilisation and charges in addition to the clinical benefits associated with its use^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT01203358	Infant, Newborn ... more >> Infant, Low Birth Weight Infant, Small for Gestational Age Infant, Premature Bronchopulmonary Dysplasia Collapse <<	Phase 2 Phase 3	Completed	-	United States, California ... more >> Stanford University Palo Alto, California, United States, 94304 United States, Connecticut Yale University New Haven, Connecticut, United States, 06504 United States, District of Columbia George Washington University Washington, District of Columbia, United States, 20052 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Georgia Emory University Atlanta, Georgia, United States, 30303 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Michigan Wayne State University Detroit, Michigan, United States, 48201 United States, New Mexico University of New Mexico Albuquerque, New Mexico, United States, 87131 United States, Ohio Cincinnati Children's Medical Center Cincinnati, Ohio, United States, 45267 Case Western Reserve University, Rainbow Babies and Children's Hospital Cleveland, Ohio, United States, 44106 United States, Tennessee University of Tennessee Memphis, Tennessee, United States, 38163 United States, Texas University of Texas Southwestern Medical Center at Dallas Dallas, Texas, United States, 75235 United States, Vermont University of Vermont Burlington, Vermont, United States, 05405 Collapse <<

• 参考文献

• [1] Dechant KL, Faulds D. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome. Drugs. 1991 Nov;42(5):877-94.

  [2] Abrahamson EL, Viswanath M, et al. Unilateral pulmonary interstitial emphysema and treatment with colfosceril palmitate. Lancet. 1993 Jun 19;341(8860):1603.

  [3] Dechant KL, Faulds D. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome. Drugs. 1991 Nov;42(5):877-94

  [4] Ishisaka DY. Exogenous surfactant use in neonates. Ann Pharmacother. 1996 Apr;30(4):389-98

  [5] Hu Y, Chen J, Xu Y, Zhou H, Huang P, Ma Y, Gao M, Cheng S, Zhou H, Lv Z. Alterations of Gut Microbiome and Metabolite Profiling in Mice Infected by Schistosoma japonicum. Front Immunol. 2020 Oct 8;11:569727

  [6] Backhouse ME, Mauskopf JA, Jones D, Wold DE, Schumacher R, Cotton R, Long WA. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial. Pharmacoeconomics. 1994 Oct;6(4):358-69

• 更多

• Collapse